Cancer is a heterogeneous disease with unique genomic and phenotypic features that differ between individual patients and even among individual tumor regions.In recent years,large-scale genomic studies and new next-ge...Cancer is a heterogeneous disease with unique genomic and phenotypic features that differ between individual patients and even among individual tumor regions.In recent years,large-scale genomic studies and new next-generation sequencing technologies have uncovered more scientifc details about tumor heterogeneity,with significant implications for the choice of specific molecular biomarkers and clinical decision making Genomic heterogeneity signifcantly contributes to the generation of a diverse cell population during tumor development and progression,representing a determining factor for variation in tumor treatment response.It has been considered a prominent contributor to therapeutic failure,and increases the likelihood of resistance to future therapies in most common cancers.The understanding of molecular heterogeneity in cancer is a fundamental component of precision oncology,enabling the identification of genomic alteration of key genes and pathways that can be targeted therapeutically.Here,we review the emerging knowledge of tumor genomics and heterogeneity,as well as potential implications for precision medicine in cancer treatment and new therapeutic discoveries.An analysis and interpretation of the TCGA database was included.展开更多
基金supported in part by the National Natural Science Foundation of China(Grant No.81770173)the National Institutes of Health(Grant No.R01 DK100858).
文摘Cancer is a heterogeneous disease with unique genomic and phenotypic features that differ between individual patients and even among individual tumor regions.In recent years,large-scale genomic studies and new next-generation sequencing technologies have uncovered more scientifc details about tumor heterogeneity,with significant implications for the choice of specific molecular biomarkers and clinical decision making Genomic heterogeneity signifcantly contributes to the generation of a diverse cell population during tumor development and progression,representing a determining factor for variation in tumor treatment response.It has been considered a prominent contributor to therapeutic failure,and increases the likelihood of resistance to future therapies in most common cancers.The understanding of molecular heterogeneity in cancer is a fundamental component of precision oncology,enabling the identification of genomic alteration of key genes and pathways that can be targeted therapeutically.Here,we review the emerging knowledge of tumor genomics and heterogeneity,as well as potential implications for precision medicine in cancer treatment and new therapeutic discoveries.An analysis and interpretation of the TCGA database was included.
